The Hyperalgesia drugs in development market research report provides comprehensive information on the therapeutics under development for Hyperalgesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hyperalgesia. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Hyperalgesia by eight companies/universities/institutes. The top development phase for Hyperalgesia is preclinical with seven drugs in that stage. The Hyperalgesia pipeline has three drugs in development by companies and five by universities/ institutes. Some of the companies in the Hyperalgesia pipeline products market are: Johns Hopkins University, SATT Conectus Alsace and Fujian Normal University.
The key targets in the Hyperalgesia pipeline products market include Phospholipase A2, Probable G Protein Coupled Receptor 19, and Mu Type Opioid Receptor.
The key mechanisms of action in the Hyperalgesia pipeline product include Mu Type Opioid Receptor Agonist with one drug in Preclinical. The Hyperalgesia pipeline products include one routes of administration with the top ROA being Oral and four key molecule types in the Hyperalgesia pipeline products market including Small Molecule, and Synthetic Peptide.
Hyperalgesia overview
Hyperalgesia is an increase in pain response. Predisposing factors include long-term opioid usage, inflammation, damage to nociceptors, damage to peripheral nerves, and psychological disorders. Treatment includes antidepressants and non-steroidal anti-inflammatory drugs (NSAIDs).
For a complete picture of Hyperalgesia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
